{
    "clinical_study": {
        "@rank": "85550", 
        "acronym": "Reliable", 
        "arm_group": {
            "arm_group_label": "MD-12-001 Stent Arm", 
            "arm_group_type": "Experimental", 
            "description": "This study includes a single arm, the MD-12-001 Stent Arm."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and effectiveness of the MD-12-001 stent\n      in the treatment of superficial femoral artery and proximal popliteal artery blockages in\n      Japanese patients."
        }, 
        "brief_title": "A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese Patients", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Arterial Occlusive Disease", 
        "condition_browse": {
            "mesh_term": "Arterial Occlusive Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Rutherford Category 2-4 (mild intermittent claudication (pain while walking)to\n             ischemic pain (pain due to decreased blood flow) at rest).\n\n          -  The target lesion(s) has evidence of narrowing or blockage and can be stented.\n\n          -  The total length of the lesion or series of lesions is estimated to be less than or\n             equal to 150 mm.\n\n          -  The target vessel reference diameter is greater than or equal to 4.0 mm and less than\n             or equal to 6.5 mm\n\n        Key Exclusion Criteria:\n\n          -  The subject has a known reaction (including allergic reaction) or sensitivity to\n             blood thinning medications, or study device materials (nickel, titanium or tantalum)\n\n          -  The subject has a known sensitivity to medical imaging substances (contract media)\n             that cannot be pretreated with medications (steroids or/and antihistamines)\n\n          -  The subject has a history of bleeding disorders (diatheses or coagulopathy).\n\n          -  The subject has kidney failure or is having dialysis treatment.\n\n          -  The subject has insufficient liver function, swelling of vein(s) caused by blood clot\n             (thrombophlebitis), uremia, systemic lupus, or deep vein blood clots.\n\n          -  Subject has Acute Limb Ischemia (a sudden loss of blood flow to the limb).\n\n          -  Subject has a history of bypass surgery on the study vessel.\n\n          -  Subject has a history of heart attack or stroke within 6 months of study procedure.\n\n          -  The subject is receiving immunosuppressive therapy (medications that lower the body's\n             normal immune response).\n\n          -  The subject is diagnosed with a severe infection (septicemia).\n\n          -  Principal investigator determines the subject's condition would prevent the subject\n             from undergoing the study procedure or cannot support a vascular bypass graft.\n\n          -  The subject with a stent previously implanted into the target vessel.\n\n          -  Subject has disease in both legs where both limbs meet the inclusion criteria and it\n             is planned to treat both limbs within 30 days.\n\n          -  Pregnant, possibly pregnant and/or nursing female subjects are excluded, as are\n             female subjects who are willing to have a baby during the trial.\n\n          -  The subject is participating in an investigational drug or another investigational\n             device study.\n\n          -  Subject has a large amount of blood clot next to the study lesion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746550", 
            "org_study_id": "MED-12-001"
        }, 
        "intervention": {
            "arm_group_label": "MD-12-001 Stent Arm", 
            "description": "MD-12-001 is a self-expanding nitinol stent", 
            "intervention_name": "MD-12-001 Stent", 
            "intervention_type": "Device", 
            "other_name": "Bard Lifestent Vascular Stent"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kitakyusyu", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }, 
                    "name": "Kokura Kinen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }, 
                    "name": "Tokeidai Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amagasaki", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }, 
                    "name": "Kansai Rosai Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Shonankamakura General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Saiseikai Yokohamashi Tobu Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }, 
                    "name": "Sendai Kousei Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashihara", 
                        "country": "Japan", 
                        "state": "Nara"
                    }, 
                    "name": "Nara Medical University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kishiwada", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Kishiwada Tokushukai Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kasukabe", 
                        "country": "Japan", 
                        "state": "Saitama"
                    }, 
                    "name": "Kasukabe Chuo General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meguro", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Toho University Ohashi Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "The Jikei University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "Kyushu University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Arm Clinical Trial in Japan for Reconstruction of Obstructive Lesions of the Superficial Femoral Artery or Proximal Popliteal Artery by Bard LifeStent.", 
        "overall_official": {
            "affiliation": "Toho University Ohashi Hospital", 
            "last_name": "Masato Nakamura", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects who are free of target limb failure at 12-months post study procedure.", 
            "safety_issue": "No", 
            "time_frame": "12-months post study procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects who are free of target limb failure.", 
                "safety_issue": "No", 
                "time_frame": "30-days, 6-, 24-, and 36-months post study procedure"
            }, 
            {
                "description": "This endpoint will assess whether the study blockage has been unblocked using ultrasound imaging assessments reviewed by an independent core laboratory.", 
                "measure": "The proportion of subjects with primary target lesion patency.", 
                "safety_issue": "No", 
                "time_frame": "30-days, 6-, 12-, 24-, and 36-months post study procedure"
            }, 
            {
                "description": "This endpoint will assess whether the study blockage has shut again; where the target vessel/lesion no longer has blood flow or where surgical bypass of the vessel is performed.", 
                "measure": "The proportion of subjects with secondary target vessel/lesion patency.", 
                "safety_issue": "No", 
                "time_frame": "30-days, 6-, 12-, 24-, and 36-months post study procedure"
            }, 
            {
                "measure": "Proportion of subjects who achieve acute procedural success.", 
                "safety_issue": "No", 
                "time_frame": "Perioperative period (period during study procedure)"
            }, 
            {
                "description": "The assessment of peripheral artery disease severity will be performed using the Rutherford Classification system.", 
                "measure": "Rutherford category assessment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30-days. 3-. 6-. 12-. 24-. 36-. 48- and 60-months post study procedure"
            }, 
            {
                "description": "The ratio of blood pressure in the lower legs to the blood pressure in the arms will be calculated and assessed as a measure of disease severity.", 
                "measure": "Ankle-brachial index measurements.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30-days, 3-, 6-, 12-, 24-, 36-, 48-, and 60-months post study procedure"
            }, 
            {
                "description": "The SF-36 Quality of Life Questionnaire (QOL) will be used to evaluate QOL changes during study participation.", 
                "measure": "Quality of Life (SF-36) Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30-days, 3- , 6-, 12-, 24-, 36-, 48-, and 60-months post study procedure"
            }, 
            {
                "description": "Major Adverse Events is defined as any death, stroke, myocardial infarction (heart attack) or target limb amputation.", 
                "measure": "Proportion of Subjects who experience Major Adverse Events.", 
                "safety_issue": "Yes", 
                "time_frame": "30-days post procedure"
            }, 
            {
                "measure": "Proportions of Subjects who experience 1) any adverse event and 2) any serious adverse event.", 
                "safety_issue": "Yes", 
                "time_frame": "through 60-months post study procedure"
            }, 
            {
                "measure": "The proportion of subjects who undergo target vessel/lesion revascularization (restoration of blood flow)", 
                "safety_issue": "Yes", 
                "time_frame": "12-, 24-, 36-, 48-, and 60-months post study procedure"
            }, 
            {
                "measure": "Proportion of subjects without stent fracture", 
                "safety_issue": "Yes", 
                "time_frame": "30-days, 6-, 12-, 24, and 36-months post study procedure"
            }
        ], 
        "source": "C. R. Bard", 
        "sponsors": {
            "collaborator": {
                "agency": "Medicon, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "C. R. Bard", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}